Repository logo
 
Publication

Monitoring COVID‐19 vaccine effectiveness against COVID‐19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022

2023-11-28Journal article Open access
Simple item page
dc.contributor.authorKislaya, Irina
dc.contributor.authorSentís, Alexis
dc.contributor.authorStarrfelt, Jostein
dc.contributor.authorNunes, Baltazar
dc.contributor.authorMartínez‐Baz, Iván
dc.contributor.authorNielsen, Katrine Finderup
dc.contributor.authorAlKerwi, Ala'a
dc.contributor.authorBraeye, Toon
dc.contributor.authorFontán‐Vela, Mario
dc.contributor.authorBacci, Sabrina
dc.contributor.authorMeijerink, Hinta
dc.contributor.authorCastilla, Jesús
dc.contributor.authorEmborg, Hanne‐Dorthe
dc.contributor.authorHansen, Christian Holm
dc.contributor.authorSchmitz, Susanne
dc.contributor.authorVan Evercooren, Izaak
dc.contributor.authorValenciano, Marta
dc.contributor.authorNardone, Anthony
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorMonge, Susana
dc.contributor.authorVEBIS‐Lot4 working group
dc.date.accessioned2024-02-14T11:14:44Z
dc.date.available2024-02-14T11:14:44Z
dc.date.issued2023-11-28
dc.description.abstractBackground: Within the ECDC-VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID-19 hospitalisation and COVID-19-related death using electronic health registries (EHR), between October 2021 and November 2022, in community-dwelling residents aged 65-79 and ≥80 years in six European countries. Methods: EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8-week follow-up periods, allowing 1 month-lag for data consolidation. Cox proportional-hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1 - aHR) × 100%. Site-specific estimates were pooled using random-effects meta-analysis. Results: For ≥80 years, considering unvaccinated as the reference, VE against COVID-19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: -27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65-79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: -3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65-79 years. The first booster VE against COVID-19-related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years. Conclusions: Successive vaccine boosters played a relevant role in maintaining protection against COVID-19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near-real-time VE monitoring in the EU/EEA and support public health decision-making.pt_PT
dc.description.sponsorshipEuropean Centre for Disease Prevention and Control, Grant/Award Numbers ECDC/2021/018, RS/2022/DTS/24104.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationInfluenza Other Respir Viruses. 2023 Nov;17(11):e13195. doi: 10.1111/irv.13195. Meta-Analysispt_PT
dc.identifier.doi10.1111/irv.13195pt_PT
dc.identifier.issn1750-2640
dc.identifier.urihttp://hdl.handle.net/10400.18/9105
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/irv.13195pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectCOVID-19-Related Deathpt_PT
dc.subjectCohort Designpt_PT
dc.subjectHospitalizationpt_PT
dc.subjectVaccine Effectivenesspt_PT
dc.subjectVacinapt_PT
dc.subjectEfetividadept_PT
dc.subjectVEBIS- LOTE 4pt_PT
dc.subjectCuidados de Saúdept_PT
dc.titleMonitoring COVID‐19 vaccine effectiveness against COVID‐19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue11pt_PT
oaire.citation.startPagee13195pt_PT
oaire.citation.titleInfluenza and Other Respiratory Virusespt_PT
oaire.citation.volume17pt_PT
person.familyNameKislaya
person.familyNameNunes
person.givenNameIrina
person.givenNameBaltazar
person.identifier.ciencia-idA815-4295-F91D
person.identifier.ciencia-idAB11-AD48-A8DF
person.identifier.orcid0000-0001-5772-2416
person.identifier.orcid0000-0001-6230-7209
person.identifier.scopus-author-id56442728800
person.identifier.scopus-author-id9133723200
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationcf6a6914-1de2-4c2a-96b1-9d617ca28a15
relation.isAuthorOfPublicationbe4efa0d-49df-4a93-bfdd-b76d9f7bf492
relation.isAuthorOfPublication.latestForDiscoverybe4efa0d-49df-4a93-bfdd-b76d9f7bf492

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Influenza Resp Viruses - 2023 - Kislaya - Monitoring COVID‐19 vaccine effectiveness against COVID‐19 hospitalisation and.pdf
Size:
1.33 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais